Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Volume: 23,583,298
Bid Ask Day's Range
0.0005 0.0006 0.0005 - 0.0007
huge volume looking strong still
In this way, Juniper can expand its presence and service benchmarks beyond its present customer base. This particular cable provider operates the single largest cable cluster in the country, with over 5 million residential and commercial customers, providing advanced voice and internet utilizing its state of the art, fiber-rich cable network.
5 million residential and commercial customers building and bring out people.
Juniper Opens Doors to Talks With Cable Provider
BOCA RATON, Fla., March 14, 2011 (GLOBE NEWSWIRE) -- Juniper Group (OTCQB:JUNP) announced today that its wholly owned telecommunications subsidiary is in discussions to provide construction services to a leading cable provider in the Mid Atlantic region.
looks like we will be opening our business all around the world.
JUNIPER GRP INC
JUNP
(Other OTC: JUNP.PK )
Last Trade: 0.0007
Trade Time: 3:58PM EST
Change: Up 0.0002 (40.00%)
Day's Range: 0.0004 - 0.0007
Volume: 93,822,298
huge volume and up 40%
expecting more greens to come.
looks good.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Spencer Pharmaceutic (SPPH)
0.29 ? 0.0 (0.00%)
Volume: 60,243 @ 11:58:08 AM ET
Bid Ask Day's Range
0.2502 0.29 0.27 - 0.35
holding
pretty solid day overall i must say.
and i was happy to see this also.
Management's objectives are focused on developing a responsible and cohesive strategy to develop and roll out our drug delivery system as shown with the recent addition of Dr. Lachance, who will be spearheading our Regulatory Affairs goals and objectives," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition, "The board of directors at its most recent meeting moved to begin the process to upgrade its listing to the OTCBB. Naturally, every move, be it to the NASDAQ or above, begins with this first step to start the process. We are building a team that is committed in developing a sustainable business for our shareholders," further added Dr. Arella.
im with you on that one, i think its very possible to close at .30! we have PR's today and what looks like a low float gradually coming up
PR's SPPH :
BOSTON, MA--(Marketwire - 11/03/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has begun the process to upgrade its listing to the OTCBB.
According to the company, it is imperative in today's economy to be fully reporting to provide shareholders with maximum transparency.
"Management's objectives are focused on developing a responsible and cohesive strategy to develop and roll out our drug delivery system as shown with the recent addition of Dr. Lachance, who will be spearheading our Regulatory Affairs goals and objectives," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition, "The board of directors at its most recent meeting moved to begin the process to upgrade its listing to the OTCBB. Naturally, every move, be it to the NASDAQ or above, begins with this first step to start the process. We are building a team that is committed in developing a sustainable business for our shareholders," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
PR's SPPH :
BOSTON, MA--(Marketwire - 11/03/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has begun the process to upgrade its listing to the OTCBB.
According to the company, it is imperative in today's economy to be fully reporting to provide shareholders with maximum transparency.
"Management's objectives are focused on developing a responsible and cohesive strategy to develop and roll out our drug delivery system as shown with the recent addition of Dr. Lachance, who will be spearheading our Regulatory Affairs goals and objectives," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition, "The board of directors at its most recent meeting moved to begin the process to upgrade its listing to the OTCBB. Naturally, every move, be it to the NASDAQ or above, begins with this first step to start the process. We are building a team that is committed in developing a sustainable business for our shareholders," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Management's objectives are focused on developing a responsible and cohesive strategy to develop and roll out our drug delivery system as shown with the recent addition of Dr. Lachance, who will be spearheading our Regulatory Affairs goals and objectives," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. In addition, "The board of directors at its most recent meeting moved to begin the process to upgrade its listing to the OTCBB. Naturally, every move, be it to the NASDAQ or above, begins with this first step to start the process. We are building a team that is committed in developing a sustainable business for our shareholders," further added Dr. Arella.
Spencer Pharmaceutical Begins Process for OTCBB Listing
BOSTON, MA--(Marketwire - 11/03/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has begun the process to upgrade its listing to the OTCBB.
According to the company, it is imperative in today's economy to be fully reporting to provide shareholders with maximum transparency.
consolidating waiting for a move.
holding strong here.
we have alot of potential for a nice run, imo everything is looking bright solid support and nice volume that keeps on coming.
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that the company has received a letter of interest by a private equity fund for a proposed important investment in the shares of the company.
According to the letter of interest, the private equity fund has requested its identity be kept confidential until further discussion and due-diligence is undertaken. However, no price has yet to be discussed nor any formal offer made.
"Although it is very flattering to be courted at this early stage, our objectives are clear and we will continue to work with our partners in licensing our technology for the Met4 as well as our extended release Ibuprofen," said Dr. Arella, President of Spencer Pharmaceutical Inc. "Naturally, if a formal offer was to be made by the private equity fund, the board of directors would consider, evaluate and recommend a course of action to its shareholders," further added Dr. Arella.
formerly Aeterna Laboratories) where he held various positions with increasing responsibilities from Associate Director Process Development, to Associate Director Regulatory Affairs and Principal Director Quality Assurance. Since 2008, Dr. Lachance has been an independent consultant in Pharmaceutical development, Regulatory Affairs and Quality Assurance and he has been active as a member of the Canadian Association of Professional Regulatory Affairs (CAPRA), the US Drug Information Association (DIA) and the American Society for Quality (ASQ).
"We are pleased that Dr. Lachance has accepted our offer and will be an active and very valuable part of our team," said Dr. Arella, President of Spencer Pharmaceutical, Inc. "As a consultant to Spencer Pharmaceutical, Dr. Lachance will provide expertise in drug development, regulatory affairs, strategic planning and submissions. He will be an important asset in our goal of achieving high standards of quality in our product development," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
spph :
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has hired the services of Dr. Yves Lachance, a regulatory affair specialist.
Dr. Lachance holds a Ph.D. in physiology and endocrinology from Laval University (Quebec, Canada) and a postdoctoral fellowship at a federal government research laboratory in Lennoxville (Canada). From 1992 to 1996, Dr. Lachance was a research associate at the University Hospital (CHUL) Research Center in Quebec City. He then joined the biopharmaceutical company Aeterna-Zentaris (formerly Aeterna Laboratories) where he held various positions with increasing responsibilities from Associate Director Process Development, to Associate Director Regulatory Affairs and Principal Director Quality Assurance. Since 2008, Dr. Lachance has been an independent consultant in Pharmaceutical development, Regulatory Affairs and Quality Assurance and he has been active as a member of the Canadian Association of Professional Regulatory Affairs (CAPRA), the US Drug Information Association (DIA) and the American Society for Quality (ASQ).
"We are pleased that Dr. Lachance has accepted our offer and will be an active and very valuable part of our team," said Dr. Arella, President of Spencer Pharmaceutical, Inc. "As a consultant to Spencer Pharmaceutical, Dr. Lachance will provide expertise in drug development, regulatory affairs, strategic planning and submissions. He will be an important asset in our goal of achieving high standards of quality in our product development," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
spph :
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that the company has received a letter of interest by a private equity fund for a proposed important investment in the shares of the company.
According to the letter of interest, the private equity fund has requested its identity be kept confidential until further discussion and due-diligence is undertaken. However, no price has yet to be discussed nor any formal offer made.
"Although it is very flattering to be courted at this early stage, our objectives are clear and we will continue to work with our partners in licensing our technology for the Met4 as well as our extended release Ibuprofen," said Dr. Arella, President of Spencer Pharmaceutical Inc. "Naturally, if a formal offer was to be made by the private equity fund, the board of directors would consider, evaluate and recommend a course of action to its shareholders," further added Dr. Arella.
The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
spph :
Spencer Pharmaceutical Receives Letter of Interest
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that the company has received a letter of interest by a private equity fund for a proposed important investment in the shares of the company.
According to the letter of interest, the private equity fund has requested its identity be kept confidential until further discussion and due-diligence is undertaken. However, no price has yet to be discussed nor any formal offer made.
"Although it is very flattering to be courted at this early stage, our objectives are clear and we will continue to work with our partners in licensing our technology for the Met4 as well as our extended release Ibuprofen," said Dr. Arella, President of Spencer Pharmaceutical Inc. "Naturally, if a formal offer was to be made by the private equity fund, the board of directors would consider, evaluate and recommend a course of action to its shareholders," further added Dr. Arella.
The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
spph :
news
Spencer Pharmaceutical Hires Regulatory Affairs Specialist
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has hired the services of Dr. Yves Lachance, a regulatory affair specialist.
Dr. Lachance holds a Ph.D. in physiology and endocrinology from Laval University (Quebec, Canada) and a postdoctoral fellowship at a federal government research laboratory in Lennoxville (Canada). From 1992 to 1996, Dr. Lachance was a research associate at the University Hospital (CHUL) Research Center in Quebec City. He then joined the biopharmaceutical company Aeterna-Zentaris (formerly Aeterna Laboratories) where he held various positions with increasing responsibilities from Associate Director Process Development, to Associate Director Regulatory Affairs and Principal Director Quality Assurance. Since 2008, Dr. Lachance has been an independent consultant in Pharmaceutical development, Regulatory Affairs and Quality Assurance and he has been active as a member of the Canadian Association of Professional Regulatory Affairs (CAPRA), the US Drug Information Association (DIA) and the American Society for Quality (ASQ).
"We are pleased that Dr. Lachance has accepted our offer and will be an active and very valuable part of our team," said Dr. Arella, President of Spencer Pharmaceutical, Inc. "As a consultant to Spencer Pharmaceutical, Dr. Lachance will provide expertise in drug development, regulatory affairs, strategic planning and submissions. He will be an important asset in our goal of achieving high standards of quality in our product development," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Spencer Pharmaceutical Hires Regulatory Affairs Specialist
BOSTON, MA--(Marketwire - 11/02/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has hired the services of Dr. Yves Lachance, a regulatory affair specialist.
Dr. Lachance holds a Ph.D. in physiology and endocrinology from Laval University (Quebec, Canada) and a postdoctoral fellowship at a federal government research laboratory in Lennoxville (Canada). From 1992 to 1996, Dr. Lachance was a research associate at the University Hospital (CHUL) Research Center in Quebec City. He then joined the biopharmaceutical company Aeterna-Zentaris (formerly Aeterna Laboratories) where he held various positions
we are up and green this morning!
0.304 ? 0.024 (8.57%)
Volume: 134,626 @ 11:16:58 AM ET
Bid Ask Day's Range
0.26 0.3 0.26 - 0.304
0.3 ? 0.0 (0.00%)
Volume: 41,333 @ 11:37:28 AM ET
Bid Ask Day's Range
0.28 0.3 0.28 - 0.309
lets get ahead.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
We are pleased to be working with another group in the development of treatments for CNS related diseases. As many current patented drugs are becoming free of royalties, our technology would extend the patent of treatments in Alzeimers and Parkinsons," said Dr. Arella, President of Spencer Pharmaceutical Inc. "CNS disease treatments are one of the areas where our technology can be of use in extending the life of the patents, but we are also investigating many other areas such as anti-psychotic and anti-depressor drugs," further added Dr. Arella.
news spph :
BOSTON, MA--(Marketwire - 11/01/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has signed a preliminary cooperative development agreement with National Pharmaceutical Corp.
According to the agreement, Spencer and National will develop central nervous disease treatments in the areas of Alzheimer and Parkinson using Spencer's drug delivery as the primary platform. The preliminary agreement calls for a share swap of 20 million restricted shares. The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
"We are pleased to be working with another group in the development of treatments for CNS related diseases. As many current patented drugs are becoming free of royalties, our technology would extend the patent of treatments in Alzeimers and Parkinsons," said Dr. Arella, President of Spencer Pharmaceutical Inc. "CNS disease treatments are one of the areas where our technology can be of use in extending the life of the patents, but we are also investigating many other areas such as anti-psychotic and anti-depressor drugs," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
news " spph
Spencer Pharmaceutical Partners With National Pharmaceutical in the Development of Central Nervous System Disease Treatments
BOSTON, MA--(Marketwire - 11/01/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has signed a preliminary cooperative development agreement with National Pharmaceutical Corp.
According to the agreement, Spencer and National will develop central nervous disease treatments in the areas of Alzheimer and Parkinson using Spencer's drug delivery as the primary platform. The preliminary agreement calls for a share swap of 20 million restricted shares. The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
"We are pleased to be working with another group in the development of treatments for CNS related diseases. As many current patented drugs are becoming free of royalties, our technology would extend the patent of treatments in Alzeimers and Parkinsons," said Dr. Arella, President of Spencer Pharmaceutical Inc. "CNS disease treatments are one of the areas where our technology can be of use in extending the life of the patents, but we are also investigating many other areas such as anti-psychotic and anti-depressor drugs," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
According to the agreement, Spencer and National will develop central nervous disease treatments in the areas of Alzheimer and Parkinson using Spencer's drug delivery as the primary platform. The preliminary agreement calls for a share swap of 20 million restricted shares. The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
consolidating we could see a move here.
Spencer Pharmaceutical Partners With National Pharmaceutical in the Development of Central Nervous System Disease Treatments
BOSTON, MA--(Marketwire - 11/01/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has signed a preliminary cooperative development agreement with National Pharmaceutical Corp.
still looking solid here